Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Astellas Signs License For Regeneron's VelocImmune To Bolster Antibody Platform

This article was originally published in PharmAsia News

Executive Summary

Astellas will license Regeneron's human monoclonal antibody discovery technology VelocImmune as part of a strategy to build a new technology platform for the development of antibody drugs, the company said March 30

You may also be interested in...



AstraZeneca License With Regeneron For VelocImmune Could Spark Industry Trend

Regeneron is seeking to sign multiple deals offering access to the next-generation human monoclonal antibody discovery technology, exec tells "The Pink Sheet" DAILY.

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

Table

View full table

Tags:
Latest Headlines

Finance Watch: Adlai Nortye Raises $97.5m In IPO, Brings US Total To 18

Amicus Piggybacks Off Galafold Commercial Infrastructure For Pombiliti + Opfolda Launch

Structure Emerges In Obesity Race With Oral GLP-1 Agonist

ViiV In It For The Long Haul In HIV Market Battle With Gilead

See All
UsernamePublicRestriction

Register

SC066094

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By